Johnson & Johnson (JNJ)vsMaxCyte Inc (MXCT)
JNJ
Johnson & Johnson
$241.00
+0.80%
HEALTHCARE · Cap: $567.28B
MXCT
MaxCyte Inc
$1.23
+2.50%
HEALTHCARE · Cap: $129.62M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 298354% more annual revenue ($96.36B vs $32.29M). JNJ leads profitability with a 21.8% profit margin vs -121.2%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
MXCT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$241.00
$104.88 premium
Intrinsic value data unavailable for MXCT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MXCT is a turnaround play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.67 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 28/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?